BML-190Also known as indomethacin morpholinylamide
Indomethacin derivative, a CB2 ligand (Ki 435 nM) described as an inverse agonist; a tool for measuring the receptor's constitutive activity.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₃H₂₃ClN₂O₄
CAS 2854-32-2
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 426.90 g/mol
Updated on
In plain terms
BML-190 derives from indomethacin, a non-steroidal anti-inflammatory drug, modified on a single chemical function. It binds to the CB2 receptor and, in cultured cells, it reduces the spontaneous activity of this receptor instead of activating it. It is a laboratory tool, with no medical use and no consumer product.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to BML-190: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of BML-190.
Map sources
- Galiègue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem, 1995 (new tab)
- Ständer S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- CB2Inverse agonistKi = 435 nM · human39 out of 100
Zhang et al., Eur J Pharm Sci 2010: in vitro metabolism of indomethacin morpholinylamide on rat liver microsomes (cites Gallant et al. 1996, Bioorg Med Chem Lett, not indexed in PubMed, for the Ki values) (new tab) · affinity for the recombinant human CB2 receptor (Gallant et al. 1996, cited by Zhang et al. 2010); inverse agonism on cAMP and inositol phosphates (New and Wong 2003)
- CB1Binding (function not established)no measured value cited
Ki greater than 20 000 nM at recombinant human CB1 (Gallant et al. 1996, cited by Zhang et al. 2010): no measurable affinity
Pharmacology
BML-190 (indomethacin morpholinylamide) is a derivative of indomethacin, a non-steroidal anti-inflammatory drug, in which the carboxylic acid function is replaced by a morpholine amide. Zhang et al. (2010) classify it among the aminoalkylindoles and recall that it was described in 1996 by Gallant et al. as a selective CB2 ligand, with a Ki of 435 nM at human CB2 and above 20,000 nM at CB1; it was then presented as a CB2 agonist. The nature of the interaction was clarified in 2003 by New and Wong: in HEK-293 cells stably expressing human CB2, the compound potentiates forskolin-induced cAMP accumulation and lowers basal inositol phosphate production when the receptor is coupled to a chimeric G protein, the opposite of an agonist effect. It therefore acts as an inverse agonist through two families of signalling pathways, Gi/o and Gq, like AM251 in the same work. This property only shows in a system where the receptor has measurable constitutive activity; it makes BML-190 a tool for detecting it. Its metabolism was characterised in vitro in rat liver microsomes, where at least fifteen products were identified by HPLC-MS/MS (Zhang et al. 2010). No in vivo, pharmacokinetic or human data were found in the sources consulted.
Key sources.
- New and Wong, FEBS Lett 2003: BML-190 and AM251 act as inverse agonists at the human CB2 receptor, cyclic AMP and inositol phosphate signalling (new tab)PMID 12586356
- Zhang et al., Eur J Pharm Sci 2010: in vitro metabolism of indomethacin morpholinylamide on rat liver microsomes (cites Gallant et al. 1996, Bioorg Med Chem Lett, not indexed in PubMed, for the Ki values) (new tab)PMID 20542112
- PubChem, BML-190, CID 2415 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound derived from an existing drug, indomethacin. It is used as a pharmacology reagent; no clinical development was found in the sources consulted.
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It derives from indomethacin, with the carboxylic acid function replaced by a morpholine amide; the methoxylated and methylated indole ring, acylated on its nitrogen by a 4-chlorobenzoyl group, is retained (chemical name and formula checked on PubChem, CID 2415).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: BML-190 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026), neither under its code nor under the name indomethacin morpholinylamide. On a literal reading, it does not fall within the « indol-3-yl methanone » family of Annex IV: carbon 3 of the indole carries a CH2-C(=O)-morpholine group (an ethanone, not a methanone) and the nitrogen a 4-chlorobenzoyl group, motifs that the text does not list; no other generic family matches. This is a reading of the text, not a decision of the ANSM. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- New and Wong, FEBS Lett 2003: BML-190 and AM251 act as inverse agonists at the human CB2 receptor, cyclic AMP and inositol phosphate signalling (new tab)PMID 12586356
- Zhang et al., Eur J Pharm Sci 2010: in vitro metabolism of indomethacin morpholinylamide on rat liver microsomes (cites Gallant et al. 1996, Bioorg Med Chem Lett, not indexed in PubMed, for the Ki values) (new tab)PMID 20542112
- PubChem, BML-190, CID 2415 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- Common name
- BML-190 (indomethacin morpholinylamide)
- IUPAC name
- 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone
- Other names
- BML190 · Indomethacin morpholinylamide · IMMA
Identifiers
- Formula
- C₂₃H₂₃ClN₂O₄
- CAS
- 2854-32-2
- PubChem CID
- 2415(new tab)
- ChEBI
- 93649(new tab)
- InChIKey
- BJSDNVVWJYDOLK-UHFFFAOYSA-N
- SMILES
- CC1=
C(C2= C(N1C(= O) C3= CC= C(C= C3) Cl) C= CC(= C2) OC) CC(= O) N4CCOCC4
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.